Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 8/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.35 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2180175 | 1.00 | ROCK2 (0.50) | ROCK2ROCK1SYKSMYD3BTK | |
| SCHEMBL1937611 | 0.90 | ROCK2 (0.64) | ROCK2ROCK1SYKSMYD3MAPK8 | |
| SCHEMBL1937613 | 0.90 | ROCK2 (0.64) | ROCK2ROCK1SYKSMYD3MAPK8 | |
| SCHEMBL1937733 | 0.84 | ALDH1A1 (0.43) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1937736 | 0.84 | ALDH1A1 (0.43) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1937151 | 0.80 | ROCK2 (0.61) | ROCK2ROCK1SYKMAPK8 | |
| SCHEMBL1937153 | 0.80 | ROCK2 (0.61) | ROCK2ROCK1SYKMAPK8 | |
| SCHEMBL1937648 | 0.79 | ROCK2 (0.77) | ROCK2ROCK1SYKBTKMAPK8 | |
| SCHEMBL1937650 | 0.79 | ROCK2 (0.77) | ROCK2ROCK1SYKBTKMAPK8 | |
| SCHEMBL1938070 | 0.76 | ALDH1A1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166161-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166161-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ROCK1, ROCK2, RHOT2 | ROCK2 2/4885ROCK1 1/4885SYK 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.